Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011–2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone

BMC Infectious Diseases

Peter A Rice²  Bao-Xi Wang¹  Fa-Xing Jiang³  Wen-Jing Le¹  Xiao-Hong Su¹  Sai Li¹ 

[1] STD Clinic, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China;Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester 01602, MA, USA;Department of Dermatology, Anhui Provincial Hospital, Hefei 230001, China

关键词: Resistance determinants;    Ceftriaxone;    Resistance plasmids;    Antimicrobial resistance;    Neisseria gonorrhoeae;   

Others  :  1118417
DOI  :  10.1186/s12879-014-0622-0

 received in 2014-10-04, accepted in 2014-11-07,  发布年份 2014

【 摘 要 】

Background

Evolving gonococcal antimicrobial resistance (AMR) poses a serious threat to public health. The aim of this study was to: update antimicrobial susceptibility data of Neisseria gonorrhoeae recently isolated in Nanjing, China and identify specific deteminants of antimicrobial resistance and gentoypes of isolates with decreased sensitivity to ceftriaxone.

Methods

334 N. gonorrhoeae isolates were collected consecutively from symptomatic men attending the Nanjing STD Clinic between April 2011 and December 2012. The minimum inhibitory concentrations (MICs) for penicillin, tetracycline, ciprofloxacin, spectinomycin and ceftriaxone were determined by agar plate dilution for each isolate. Penicillinase-producing N. gonorrhoeae (PPNG) and tetracycline-resistant N. gonorrhoeae (TRNG) were examined and typed for β-lactamase and tetM encoding plasmids respectively. Isolates that displayed elevated MICs to ceftriaxone (MIC ≥0.125 mg/L) were also tested for mutations in penA, mtrR, porB1b, ponA and pilQ genes and characterized by Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST).

Results

98.8% (330/334) of N. gonorrhoeae isolates were resistant to ciprofloxacin; 97.9% (327/334) to tetracycline and 67.7% (226/334) to penicillin. All isolates were susceptible to ceftriaxone (MIC ≤0.25 mg/L) and spectinomycin (MIC ≤32 mg/L). Plasmid mediated resistance was exhibited by 175/334 (52%) of isolates: 120/334 (36%) of isolates were PPNG and 104/334 (31%) were TRNG. 90.0% (108/120) of PPNG isolates carried the Asia type β-lactamase encoding plasmid and 96% (100/104) of TRNG isolates carried the Dutch type tetM containing plasmid. Elevated MICs for ceftriaxone were present in 15 (4.5%) isolates; multiple mutations were found in penA, mtrR, porB1b and ponA genes. The 15 isolates were distributed into diverse NG-MAST sequence types; four different non-mosaic penA alleles were identified, including one new type.

Conclusions

N. gonorrhoeae isolates in Nanjing generally retained similar antimicrobial resistance patterns to isolates obtained five years ago. Fluctuations in resistance plasmid profiles imply that genetic exchange among gonococcal strains is ongoing and is frequent. Ceftriaxone and spectinomycin remain treatments of choice of gonorrhea in Nanjing, however, decreased susceptibility to ceftriaxone and rising MICs for spectinomycin of N. gonorrhoeae isolates underscore the importance of maintaining surveillance for AMR (both phenotypic and genotypic).

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1][http://www.nhfpc.gov.cn/jkj/s3578/201404/f81a87a2fe3f453a99677a7d9d89de0c] webcite National Health and Family Planning Commision of the People’s Republic of China: 2013 Annual National Report Of Notifiable Infectious Diseases []
• [2]Global action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria Gonorrhoeae. WHO Press, Geneva; 2012.
• [3]Tapsall J: Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: some possible remedies. Expert Rev Anti Infect Ther 2006, 4:619-628.
• [4]Unemo M, Shafer WM: Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 2011, 1230:E19-E28.
• [5]Ison CA, Hussey J, Sankar KN, Evans J, Alexander S: Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.Euro Surveill 2011, 16(14).
• [6]Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422.
• [7]Barry PM, Klausner JD: The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009, 10:555-577.
• [8]Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H: Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010.Euro Surveill 2010, 15(47).
• [9]Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M: Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55:3538-3545.
• [10]Unemo M, Golparian D, Potocnik M, Jeverica S: Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011.Euro Surveill 2012, 17(25).
• [11]Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D: Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009, 58:683-687.
• [12]Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, Kawamura Y, Ezaki T: Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005, 49:137-143.
• [13]Osaka K, Takakura T, Narukawa K, Takahata M, Endo K, Kiyota H, Onodera S: Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008, 14:195-203.
• [14]Powell AJ, Tomberg J, Deacon AM, Nicholas RA, Davies C: Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance. J Biol Chem 2009, 284:1202-1212.
• [15]Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW: Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007, 51:3111-3116.
• [16]Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, Sloots TP, Tapsall JW: Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother 2010, 65:1615-1618.
• [17]Warner DM, Shafer WM, Jerse AE: Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 2008, 70:462-478.
• [18]Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM: Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995, 141(Pt 3):611-622.
• [19]Gill MJ, Simjee S, Al-Hattawi K, Robertson BD, Easmon CS, Ison CA: Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother 1998, 42:2799-2803.
• [20]Ropp PA, Hu M, Olesky M, Nicholas RA: Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002, 46:769-777.
• [21]Zhao S, Tobiason DM, Hu M, Seifert HS, Nicholas RA: The penC mutation conferring antibiotic resistance in Neisseria gonorrhoeae arises from a mutation in the PilQ secretin that interferes with multimer stability. Mol Microbiol 2005, 57:1238-1251.
• [22]Whiley DM, Jacobsson S, Tapsall JW, Nissen MD, Sloots TP, Unemo M: Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother 2010, 65:2543-2547.
• [23]Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA: Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009, 53:3744-3751.
• [24][http://www.cdc.gov/std/treatment/Ceph-R-ResponsePlanJuly30-2012.pdf] webcite Centers for Disease Control and Prevention (CDC): Cephalosporin-Resistant Neisseria Gonorrhoeae Public Health Response Plan. CDC 2012 []
• [25]Response Plan to Control and Manage the Threat of Multidrug-Resistant Gonorrhoea in Europe. ECDC, Stockholm; 2012.
• [26][http://www.ncstdc.org/show.asp?id=967] webcite National Center for STD Control, China CDC: Brief report of Chinese Gonococcal Surveillance. []
• [27]Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009 Commun Dis Intell Q Rep 2011, 35:2-7.
• [28]Lahra MM: Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2010. Commun Dis Intell Q Rep 2012, 36:95-100.
• [29]Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in the WHO western Pacific region 1992–4 Genitourin Med 1997, 73:355-361.
• [30]Wang QQ, Zhang GC (Eds): Gonorrhea In Guidelines for Diagnosis and Treatment of Sexually Transmitted Diseases [in Chinese]. Shanghai Scientific and Technological Literature Press, Shanghai; 2007.
• [31]Bala M, Kakran M, Singh V, Sood S, Ramesh V: Monitoring antimicrobial resistance in Neisseria gonorrhoeae in selected countries of the WHO South-East Asia Region between 2009 and 2012: a retrospective analysis. Sex Transm Infect 2013, 89(4):iv28-iv35.
• [32]Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes CM: Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis 2013, 13:762-768.
• [33]Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA: Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013, 89(4):iv5-iv10.
• [34]Antimicrobial Resistance Global Report on Surveillance: 2014 Summary. WHO Press, Geneva; 2014.
• [35]Tapsall J: Antimicrobial Resistance in Neisseria Gonorrhoeae. WHO Press, Geneva; 2001.
• [36]Sherrard J, Barlow D: Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996, 72:422-426.
• [37]Neisseria gonorrhoeae In Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA; 2012:100-102.
• [38]Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C: Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012, 67:1858-1860.
• [39]Su X, Jiang F, Dai X, Sun H, Ye S: Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999–2006. Sex Transm Dis 2007, 34:995-999.
• [40]Sng EH, Yeo KL, Rajan VS: Simple method for detecting penicillinase-producing Neisseria gonorrhoeae and Staphylococcus aureus. Br J Vener Dis 1981, 57:141-142.
• [41]Gorwitz RJ, Nakashima AK, Moran JS, Knapp JS: Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988–1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ 1993, 42:29-39.
• [42]Turner A, Gough KR, Leeming JP: Molecular epidemiology of tetM genes in Neisseria gonorrhoeae. Sex Transm Infect 1999, 75:60-66.
• [43]Palmer HM, Leeming JP, Turner A: A multiplex polymerase chain reaction to differentiate beta-lactamase plasmids of neisseria gonorrhoeae. J Antimicrob Chemother 2000, 45:777-782.
• [44]Liao M, Gu WM, Yang Y, Dillon JA: Analysis of mutations in multiple loci of Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone. J Antimicrob Chemother 2011, 66:1016-1023.
• [45]Lee SG, Lee H, Jeong SH, Yong D, Chung GT, Lee YS, Chong Y, Lee K: Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010, 65:669-675.
• [46]Ohnishi M, Watanabe Y, Ono E, Takahashi C, Oya H, Kuroki T, Shimuta K, Okazaki N, Nakayama S, Watanabe H: Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother 2010, 54:1060-1067.
• [47]Martin I, Sawatzky P, Allen V, Hoang L, Lefebvre B, Mina N, Wong T, Gilmour M: Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001–2010. Sex Transm Dis 2012, 39:316-323.
• [48]Chen CC, Lin KY, Li SY: The role of penicillin-binding protein 2 (PBP2) in the cephalosporin susceptibility of Neisseria gonorrhoeae and the need for consensus in naming of PBP2. J Formos Med Assoc 2012, 111:665-666.
• [49]Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG: Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011, 55:703-712.
• [50]Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG: Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004, 189:1497-1505.
• [51]Ohneck EA, Zalucki YM, Johnson PJ, Dhulipala V, Golparian D, Unemo M, Jerse AE, Shafer WM: A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae. MBio 2011, 2:e00187-11.
• [52]Yang Y, WL ZC, Gu W: Study of antimicrobial susceptibilities and molecular resistance determines in Neisseria gonorrhoeae isolated in Shanghai. Chin J Lab Med 2009, 32:1173-1175.
• [53]Jiang Y, LJ XY, Lin HL, Wang YX: Study on drug resistance of 103 strains of Neisseria gonorrhoeae. Practical Preventive Medicine 2013, 20:345-347.
• [54]Zhong N, ZW WF, Zhang LF, Lu YZ: Analysis on the drug-resistance of Nersseria gonorrhoeae to antibiotics in Hainan area from 2006–2011. Chin J Derm Venereol 2013, 27:56-57.
• [55]Sethi S, Golparian D, Bala M, Dorji D, Ibrahim M, Jabeen K, Unemo M: Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from India, Pakistan and Bhutan in 2007–2011. BMC Infect Dis 2013, 13:35. BioMed Central Full Text
• [56]Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M: Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis 2013, 13:40. BioMed Central Full Text
• [57]Lee H, Hong SG, Soe Y, Yong D, Jeong SH, Lee K, Chong Y: Trends in antimicrobial resistance of Neisseria gonorrhoeae isolated from Korean patients from 2000 to 2006. Sex Transm Dis 2011, 38:1082-1086.
• [58]Martin I, Jayaraman G, Wong T, Liu G, Gilmour M: Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000–2009. Sex Transm Dis 2011, 38:892-898.
• [59]Dillon JA, Trecker MA, Thakur SD: Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect 2013, 89(4):iv36-iv41.
• [60]Kubanova A, Frigo N, Kubanov A, Sidorenko S, Lesnaya I, Polevshikova S, Solomka V, Bukanov N, Domeika M, Unemo M: The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005–2008.Euro Surveill 2010, 15(14).
• [61]Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ: The European gonococcal antimicrobial surveillance programme, 2009.Euro Surveill 2011, 16(42).
• [62]Cole MJ, Chisholm SA, Hoffmann S, Stary A, Lowndes CM, Ison CA: European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010, 86:427-432.
• [63]Gonococcal Antimicrobial Susceptibility Surveillance in Europe 2011. ECDC, Stockholm; 2013.
• [64]Australian Gonococcal Surveillance Programme annual report, 2010 Commun Dis Intell Q Rep 2011, 35:229-236.
• [65]Ndowa FJ, Francis JM, Machiha A, Faye-Kette H, Fonkoua MC: Gonococcal antimicrobial resistance: perspectives from the African region. Sex Transm Infect 2013, 89(4):iv11-iv15.
• [66]Mehta SD, Maclean I, Ndinya-Achola JO, Moses S, Martin I, Ronald A, Agunda L, Murugu R, Bailey RC, Melendez J, Zenilman JM: Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother 2011, 55:3882-3888.
• [67]Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M: Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1267-1270.
• [68]Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, Lovgren M, Haldane D, Caeseele PV, Horsman G, Garceau R, Ratnam S, Wong T, Gilmour M: Antimicrobial susceptibilities and distribution of sequence types of Neisseria gonorrhoeae isolates in Canada: 2010. Can J Microbiol 2013, 59:671-678.
• [69]Hottes TS, Lester RT, Hoang LM, McKay R, Imperial M, Gilbert M, Patrick D, Wong T, Martin I, Ogilvie G: Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013, 40:46-51.
• [70]Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000–2010 MMWR Morb Mortal Wkly Rep 2011, 60:873-877.
• [71]Unemo M, Golparian D, Skogen V, Olsen AO, Moi H, Syversen G, Hjelmevoll SO: Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway. Antimicrob Agents Chemother 2013, 57:1057-1061.
• [72]Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, Khan WN, Stein DC: Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987, 317:272-278.
• [73]Phillips I: Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet 1976, 2:656-657.
• [74]Dillon JA, Yeung KH: Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 1989, 2(Suppl):S125-S133.
• [75]Fayemiwo SA, Muller EE, Gumede L, Lewis DA: Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011, 38:329-333.
• [76]Trembizki E, Buckley C, Lawrence A, Lahra M, Whiley D: Characterisation of a novel Neisseria gonorrhoeae penicillinase-producing plasmid isolated in Australia in 2012. Antimicrob Agents Chemother 2014, 58:4984-4985.
• [77]Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T, Ohnishi M: Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. Antimicrob Agents Chemother 2013, 57:5225-5232.
• [78]Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P: High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273-1280.
• [79]Hjelmevoll SO, Golparian D, Dedi L, Skutlaberg DH, Haarr E, Christensen A, Jorgensen S, Nilsen OJ, Unemo M, Skogen V: Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. Eur J Clin Microbiol Infect Dis 2012, 31:1181-1186.
• [80]Golparian D, Hellmark B, Fredlund H, Unemo M: Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010, 86:454-460.
• [81]Gose S, Nguyen D, Lowenberg D, Samuel M, Bauer H, Pandori M: Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA. BMC Infect Dis 2013, 13:570. BioMed Central Full Text
• [82]Tomberg J, Unemo M, Davies C, Nicholas RA: Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 2010, 49:8062-8070.
• [83]Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections MMWR Morb Mortal Wkly Rep 2012, 61:590-594.
• [84]Bignell C, Fitzgerald M: UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011, 22:541-547.
• [85]Bignell C, Unemo M: 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013, 24:85-92.
• [86]Yuan LF, Yin YP, Dai XQ, Pearline RV, Xiang Z, Unemo M, Chen XS: Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011, 38:764-768.
• [87]Read PJ, Limnios EA, McNulty A, Whiley D, Lahra MM: One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health 2013, 10:460-462.
• [88]YC M, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G: Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013, 68:1445-1447.
• [89]Deguchi T, Yasuda M, Ito S: Management of pharyngeal gonorrhea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother 2012, 56:4039-4040. author reply 4041–4032